BCYC
Price
$5.70
Change
-$0.30 (-5.00%)
Updated
Feb 4, 02:22 PM (EDT)
Capitalization
415.17M
27 days until earnings call
Intraday BUY SELL Signals
STOK
Price
$31.35
Change
-$2.44 (-7.22%)
Updated
Feb 4, 03:19 PM (EDT)
Capitalization
1.93B
35 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

BCYC vs STOK

Header iconBCYC vs STOK Comparison
Open Charts BCYC vs STOKBanner chart's image
Bicycle Therapeutics
Price$5.70
Change-$0.30 (-5.00%)
Volume$100
Capitalization415.17M
Stoke Therapeutics
Price$31.35
Change-$2.44 (-7.22%)
Volume$300
Capitalization1.93B
BCYC vs STOK Comparison Chart in %
BCYC
Daily Signal:
Gain/Loss:
STOK
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
BCYC vs. STOK commentary
Feb 04, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BCYC is a Hold and STOK is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Feb 04, 2026
Stock price -- (BCYC: $6.00 vs. STOK: $33.79)
Brand notoriety: BCYC and STOK are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BCYC: 269% vs. STOK: 63%
Market capitalization -- BCYC: $415.17M vs. STOK: $1.93B
BCYC [@Biotechnology] is valued at $415.17M. STOK’s [@Biotechnology] market capitalization is $1.93B. The market cap for tickers in the [@Biotechnology] industry ranges from $118.13B to $0. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BCYC’s FA Score shows that 1 FA rating(s) are green whileSTOK’s FA Score has 1 green FA rating(s).

  • BCYC’s FA Score: 1 green, 4 red.
  • STOK’s FA Score: 1 green, 4 red.
According to our system of comparison, STOK is a better buy in the long-term than BCYC.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BCYC’s TA Score shows that 3 TA indicator(s) are bullish while STOK’s TA Score has 5 bullish TA indicator(s).

  • BCYC’s TA Score: 3 bullish, 5 bearish.
  • STOK’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, STOK is a better buy in the short-term than BCYC.

Price Growth

BCYC (@Biotechnology) experienced а -15.13% price change this week, while STOK (@Biotechnology) price change was +14.50% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.39%. For the same industry, the average monthly price growth was +1.48%, and the average quarterly price growth was +33.05%.

Reported Earning Dates

BCYC is expected to report earnings on Mar 03, 2026.

STOK is expected to report earnings on Mar 11, 2026.

Industries' Descriptions

@Biotechnology (-2.39% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
STOK($1.93B) has a higher market cap than BCYC($415M). STOK YTD gains are higher at: 6.459 vs. BCYC (-15.254). STOK has higher annual earnings (EBITDA): 29.1M vs. BCYC (-245.86M). BCYC has more cash in the bank: 648M vs. STOK (248M). STOK has less debt than BCYC: STOK (2.91M) vs BCYC (5.74M). STOK has higher revenues than BCYC: STOK (206M) vs BCYC (28.3M).
BCYCSTOKBCYC / STOK
Capitalization415M1.93B22%
EBITDA-245.86M29.1M-845%
Gain YTD-15.2546.459-236%
P/E RatioN/A49.69-
Revenue28.3M206M14%
Total Cash648M248M261%
Total Debt5.74M2.91M197%
FUNDAMENTALS RATINGS
BCYC vs STOK: Fundamental Ratings
BCYC
STOK
OUTLOOK RATING
1..100
35
VALUATION
overvalued / fair valued / undervalued
1..100
15
Undervalued
82
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9651
PRICE GROWTH RATING
1..100
7937
P/E GROWTH RATING
1..100
1004
SEASONALITY SCORE
1..100
8532

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BCYC's Valuation (15) in the null industry is significantly better than the same rating for STOK (82). This means that BCYC’s stock grew significantly faster than STOK’s over the last 12 months.

BCYC's Profit vs Risk Rating (100) in the null industry is in the same range as STOK (100). This means that BCYC’s stock grew similarly to STOK’s over the last 12 months.

STOK's SMR Rating (51) in the null industry is somewhat better than the same rating for BCYC (96). This means that STOK’s stock grew somewhat faster than BCYC’s over the last 12 months.

STOK's Price Growth Rating (37) in the null industry is somewhat better than the same rating for BCYC (79). This means that STOK’s stock grew somewhat faster than BCYC’s over the last 12 months.

STOK's P/E Growth Rating (4) in the null industry is significantly better than the same rating for BCYC (100). This means that STOK’s stock grew significantly faster than BCYC’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BCYCSTOK
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
83%
Bearish Trend 2 days ago
89%
Momentum
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
77%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
84%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
86%
Bullish Trend 2 days ago
84%
Advances
ODDS (%)
Bullish Trend 9 days ago
81%
Bullish Trend 2 days ago
86%
Declines
ODDS (%)
Bearish Trend 6 days ago
88%
Bearish Trend 10 days ago
85%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
76%
Aroon
ODDS (%)
Bearish Trend 2 days ago
81%
Bullish Trend 2 days ago
80%
View a ticker or compare two or three
Interact to see
Advertisement
BCYC
Daily Signal:
Gain/Loss:
STOK
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
OAZIX33.350.13
+0.39%
Oakmark International R6
PJGZX24.330.08
+0.33%
PGIM Jennison Focused Value Z
AVUSX21.82-0.06
-0.27%
Avantis® U.S. Equity Institutional
GDGIX32.31-0.33
-1.01%
Sit Global Dividend Growth I
BIALX28.50-0.71
-2.43%
Brown Advisory Global Leaders Investor

BCYC and

Correlation & Price change

A.I.dvisor indicates that over the last year, BCYC has been loosely correlated with NRIX. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if BCYC jumps, then NRIX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BCYC
1D Price
Change %
BCYC100%
-7.55%
NRIX - BCYC
53%
Loosely correlated
-1.76%
NGNE - BCYC
51%
Loosely correlated
-4.20%
SYRE - BCYC
51%
Loosely correlated
+1.65%
RLAY - BCYC
48%
Loosely correlated
+6.38%
SLDB - BCYC
47%
Loosely correlated
+1.71%
More

STOK and

Correlation & Price change

A.I.dvisor indicates that over the last year, STOK has been loosely correlated with QTTB. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if STOK jumps, then QTTB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To STOK
1D Price
Change %
STOK100%
+9.81%
QTTB - STOK
49%
Loosely correlated
+6.28%
DNLI - STOK
48%
Loosely correlated
-4.22%
BCYC - STOK
48%
Loosely correlated
-7.55%
NGNE - STOK
47%
Loosely correlated
-4.20%
RGNX - STOK
45%
Loosely correlated
+0.74%
More